MX9604019A - Derivados de biotina. - Google Patents

Derivados de biotina.

Info

Publication number
MX9604019A
MX9604019A MX9604019A MX9604019A MX9604019A MX 9604019 A MX9604019 A MX 9604019A MX 9604019 A MX9604019 A MX 9604019A MX 9604019 A MX9604019 A MX 9604019A MX 9604019 A MX9604019 A MX 9604019A
Authority
MX
Mexico
Prior art keywords
biothyne
asp
arg
missing
derivatives
Prior art date
Application number
MX9604019A
Other languages
English (en)
Inventor
Alfred Jonczyk
Simon Goodman
Beate Diefenbach
Original Assignee
Merck Patent Gmbh
Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Haftung filed Critical Merck Patent Gmbh
Publication of MX9604019A publication Critical patent/MX9604019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

y R1 significa X-Arg-Gl-Asp-Y, A-Cys(R2)-B-U o ciclo-(Arg-Gly-Asp-Z) donde Z está unido por la cadena lateral a Q, si Q falta, a biotina, y A, B, U, X, Y, Z y n tienen los significados indicados en la reivindicacion 1, y sus sales, se pueden utilizar en calidad de inhibidores de las integrinas, en particular para prevenir y tratar enfermedades circulatorias, trombosis, infarto cardíaco, enfermedades coronarias, arterioesclerosis, enfermedades angiogénicas y para tratar tumores.
MX9604019A 1995-09-14 1996-09-11 Derivados de biotina. MX9604019A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19534016A DE19534016A1 (de) 1995-09-14 1995-09-14 Biotinderivate

Publications (1)

Publication Number Publication Date
MX9604019A true MX9604019A (es) 1997-03-29

Family

ID=7772112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604019A MX9604019A (es) 1995-09-14 1996-09-11 Derivados de biotina.

Country Status (23)

Country Link
EP (1) EP0771818B1 (es)
JP (1) JP4127325B2 (es)
KR (1) KR970015597A (es)
CN (1) CN1168738C (es)
AT (1) ATE215558T1 (es)
AU (1) AU719307B2 (es)
BR (1) BR9603741A (es)
CA (1) CA2185394C (es)
CZ (1) CZ291506B6 (es)
DE (2) DE19534016A1 (es)
DK (1) DK0771818T3 (es)
ES (1) ES2174007T3 (es)
HU (1) HUP9602223A3 (es)
MX (1) MX9604019A (es)
NO (1) NO314694B1 (es)
PL (1) PL316069A1 (es)
PT (1) PT771818E (es)
RU (1) RU2171807C2 (es)
SI (1) SI0771818T1 (es)
SK (1) SK283129B6 (es)
TW (1) TW517063B (es)
UA (1) UA41981C2 (es)
ZA (1) ZA967765B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2593600A (en) 1998-12-23 2000-07-12 G.D. Searle & Co. Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
EP1257566A4 (en) * 2000-02-11 2005-06-15 Univ Duke METHOD FOR THE TREATMENT OF EYE DISEASES
KR100778633B1 (ko) * 2007-04-13 2007-11-28 성균관대학교산학협력단 비오틴과 비오틴-폴리에틸렌글리콜이 접합된 ｇｌｐ-1유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
EP2259768B1 (en) * 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN113827591B (zh) * 2021-11-09 2023-06-09 上海市肺科医院 生物素在制备治疗脓毒症药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315076B2 (es) * 1973-09-27 1978-05-22
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
DE4336758A1 (de) * 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren

Also Published As

Publication number Publication date
ATE215558T1 (de) 2002-04-15
AU719307B2 (en) 2000-05-04
PT771818E (pt) 2002-09-30
CA2185394C (en) 2007-05-01
JPH09124692A (ja) 1997-05-13
EP0771818B1 (de) 2002-04-03
PL316069A1 (en) 1997-03-17
DK0771818T3 (da) 2002-07-29
DE19534016A1 (de) 1997-03-20
SK115696A3 (en) 1997-05-07
DE59608995D1 (de) 2002-05-08
HUP9602223A2 (en) 1997-06-30
RU2171807C2 (ru) 2001-08-10
AU6551896A (en) 1997-03-20
UA41981C2 (uk) 2001-10-15
NO963851D0 (no) 1996-09-13
CZ291506B6 (cs) 2003-03-12
ES2174007T3 (es) 2002-11-01
SK283129B6 (sk) 2003-02-04
JP4127325B2 (ja) 2008-07-30
HUP9602223A3 (en) 1998-03-02
CN1168738C (zh) 2004-09-29
CN1153784A (zh) 1997-07-09
BR9603741A (pt) 1998-06-02
EP0771818A3 (de) 1997-07-02
ZA967765B (en) 1997-03-26
HU9602223D0 (en) 1996-10-28
KR970015597A (ko) 1997-04-28
CZ262996A3 (cs) 1998-02-18
TW517063B (en) 2003-01-11
EP0771818A2 (de) 1997-05-07
CA2185394A1 (en) 1997-03-15
SI0771818T1 (en) 2002-10-31
NO314694B1 (no) 2003-05-05
NO963851L (no) 1997-03-17

Similar Documents

Publication Publication Date Title
TW372232B (en) Phenylalanine derivatives
SE9103612D0 (sv) New peptide derivatives
RU94022258A (ru) Новые сульфониламинопиримидины
SE9704709D0 (sv) Pharmaceutically active compounds
DK0608759T3 (da) Piperazinderivater
TR199901962T2 (xx) Bisiklik amino asitler.
DE69623899D1 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
MX9604019A (es) Derivados de biotina.
CA2234980A1 (en) Cyclopeptide derivatives
DE69304573D1 (de) Aminsäurederivate mit antithrombotischer Wirkung
PT659082E (pt) Utilizacao de inibidores de citocromo p450 para inibir o metabolismo de acridina substituida com azoto
MY106333A (en) Adenosine derivatives,their production and use.
ECSP941031A (es) Derivados de timosina alfa 1
TW221438B (es)
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
NO944093D0 (no) Lineære adhesjonsinhibitorer
ATE88634T1 (de) Arzneimittel zur behandlung von herzinsuffizienz.
DE69106008D1 (de) Behandlung von Schlaf-Apnoea mit Azapironderivaten.
DE68909025D1 (de) Mittel zur Verhinderung von Zahnbelagbildung.
DK455185A (da) Pyridinderivater
ATE150309T1 (de) Intravenös verabreichbare wässrige lösung von sulfametrol und trimethoprim
DE69905144D1 (de) N,N'-Diacylthiocystine
YU2394A (sh) Lizin so 6-hloro-5-fluoro-3-(-2-tenoil)-2-oksindol-1-karboksamida
SG4595G (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
TH33845A (es)

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees